Alpha Mannosidosis

A Global Strategic Business Report

MCP16142

RESEARCH DASHBOARD

OCT 2025

RELEASE DATE

448

EXECUTIVE POOL

5850

PRICE

92

EXPERT INPUTS

42

COMPANIES

123

DATA TABLES

194

PAGES

7

EDITION

WHAT'S BEHIND OUR DATA?

140857226

DOMAIN TRANSCRIPTS

6080276

BRANDS TRACKED

1729341

FEATURED COMPANIES

22574

TOPICS COVERED

82719

MARKET SEGMENTS

91

KEY INDUSTRIES

1574

CURATION TEAM

4761909

DECISION MAKERS

EXECUTIVE ENGAGEMENTS BY TIER (29)

4

CXO

6

VICE PRESIDENT

2

DIRECTOR

8

MANAGER

9

MARKETING

REQUEST FULL-STACK INDEX Includes 350+ pages validated sources

QUESTIONNAIRE EXECUTIVES DATA ROOM

OUR EXPERT PANELS

Panelists are carefully chosen based on their domain expertise and market influence.

Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.

INFLUENCER INVITEE

WHY PARTICIPATE?

Expertise to the Power of YOU!

Collaborative Insights - Expand your deep domain insights from participants at competitive companies worldwide while you share your own!
Global Acumen Alerts - Expand your intelligence on your areas of interest by enabling our “Email Alerts” feature drawing from other influencers’ project participation.
Enterprise-wide Project Discounts - Discounts start @ 10% and build up as more participants support our ongoing projects in your space.
Complimentary Copies - We highly recommend collaboration with your team to draw upon their geographical domain expertise. Our platform enables collaborative engagements with 10 peers. When you or any of your team members purchase the report, the entire team will receive complimentary copies with full stack access to our data and updates for one year.
Annual Digital Subscription to one of the business publications or $100 value gift card - No Purchase Required! The lead participant will receive the digital subscription

The Economist
MIT Technology Review
Harvard Business Review

Note - Offer is limited to one participant per company. Offer may be withdrawn at anytime without notice once our annual maximum participation of leading players is fulfilled. Offer by invitation only, to enterprise executives in from companies featured in the project ranked. If you’ve received our initation, you’re qualified! If not, you may check your eligibility by registering to join our Project Expert Panel. Typically you must be have a Marketing, Strategy, Product Management or Business Development, role as a CXO or VP or Director or Manager directly involved with the P&L of the products or services covered in the report. You must complete all modules in the Primary Research Data Simulator.

MARKETGLASS

BASIC

Annual Prepaid Subscription
Single-User
10,000 Data Room Credits/Month
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use MarketGlass^TM Data Templates For Your Own Enterprise Data to Build Bespoke Research Reports.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.

PREMIUM

Annual Prepaid Subscription
One Research Project With One Complimentary Update/Year
10-User License
10-User Peer-to-Peer Collaborative Features
200 Domain Expert Insights (With Name, Company, and Date)
50,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

ENTERPRISE

Annual Prepaid Subscription
Four Research Projects With One Complimentary Update/Year
25-User License
25-User Peer-to-Peer Collaborative Engagements
500 Domain Expert Insights (With Name, Company, and Date)
150,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

HIGHLIGHTS & REPORT INDEX

Global Alpha Mannosidosis Market to Reach US$13.1 Billion by 2030

The global market for Alpha Mannosidosis estimated at US$6.9 Billion in the year 2024, is expected to reach US$13.1 Billion by 2030, growing at a CAGR of 11.4% over the analysis period 2024-2030. Bone Marrow Transplant (BMT), one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$6.3 Billion by the end of the analysis period. Growth in the Enzyme Replacement Therapy (ERT) segment is estimated at 14.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.9 Billion While China is Forecast to Grow at 10.8% CAGR

The Alpha Mannosidosis market in the U.S. is estimated at US$1.9 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.0 Billion by the year 2030 trailing a CAGR of 10.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.4% and 9.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR.

Global Alpha Mannosidosis Market - Key Trends & Drivers Summarized

What Is Alpha Mannosidosis and Why Does It Require Specialized Treatment?

Alpha Mannosidosis is a rare genetic lysosomal storage disorder characterized by the inability of the body to break down certain sugar molecules due to a deficiency of the enzyme alpha-mannosidase. This leads to a buildup of harmful substances in the body, causing progressive damage to tissues and organs. The condition affects multiple systems, including the central nervous system, skeletal system, and immune system, leading to developmental delays, hearing loss, and skeletal abnormalities. Without treatment, Alpha Mannosidosis can severely impact quality of life, necessitating the development of specialized therapies.

How Are Emerging Therapies Changing the Treatment Landscape?

Treatment options for Alpha Mannosidosis have evolved over time, with enzyme replacement therapy (ERT) becoming a key therapeutic option. ERT involves providing patients with synthetic enzymes to replace the deficient alpha-mannosidase, helping to reduce the buildup of toxic substances. Advances in gene therapy are also being explored, with the goal of providing long-term correction of the genetic defect responsible for the disorder. Stem cell transplantation is another treatment avenue, particularly for severe cases. These emerging therapies are offering hope for better management of Alpha Mannosidosis, improving patient outcomes and life expectancy.

How Is Patient Advocacy Influencing Market Dynamics for Rare Diseases Like Alpha Mannosidosis?

Given that Alpha Mannosidosis is a rare disease, patient advocacy groups have played a significant role in driving awareness and funding for research. These organizations have been instrumental in connecting patients with specialized care and supporting clinical trials for new therapies. The increasing availability of orphan drug designations, which provide financial incentives for companies developing treatments for rare diseases, has also spurred innovation in this market. Patient advocacy and the support for orphan drug development are helping to drive research and availability of treatments for Alpha Mannosidosis.

What Factors Are Driving Growth in the Alpha Mannosidosis Market?

The growth in the Alpha Mannosidosis market is driven by several factors, including advancements in enzyme replacement therapies, the rise of gene therapy research, and growing awareness of rare diseases. The availability of orphan drug designations and government incentives has encouraged pharmaceutical companies to invest in the development of new treatments for Alpha Mannosidosis. Moreover, increasing patient advocacy and better diagnostic tools are improving early detection and intervention, leading to better patient outcomes. The expanding focus on rare diseases by healthcare providers and biopharmaceutical companies is further propelling growth in this niche market.

SCOPE OF STUDY

The report analyzes the Alpha Mannosidosis market by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Type I, Type II, Type III); Treatment (Bone Marrow Transplant (BMT), Enzyme Replacement Therapy (ERT)).

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World..

SELECT PLAYERS

AllStripes; Centogene AG; Chiesi Espana S.A.; Chiesi Farmaceutici SpA; Chiesi Global Rare Disease; Chiesi Limited; Chiesi Pharma AB; Chiesi USA, Inc.; Creative BioMart; SmartPharm Therapeutics;

AI INTEGRATIONS

We’re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy

How Trump’s Tariffs Impact the Market? The Big Question on Everyone’s Mind

Alpha Mannosidosis – Global Key Competitors Percentage Market Share in 2024 (E)

Competitive Market Presence - Strong/Active/Niche/Trivial for 42 Players Worldwide in 2024 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Growing Awareness of Rare Diseases and Genetic Disorders Driving Treatment Demand

Increasing Availability of Enzyme Replacement Therapy (ERT) for Alpha Mannosidosis

Advancements in Gene Therapy Research for Long-term Management

Expansion of Diagnostic Capabilities for Early Detection of Alpha Mannosidosis

Rising Patient Advocacy and Government Funding for Rare Disease Treatment

Increasing Interest in Stem Cell and Bone Marrow Transplantation for Alpha Mannosidosis

Technological Innovations in Biomarker Discovery for Early-stage Treatment

Growing Focus on Developing Orphan Drugs for Alpha Mannosidosis

Expansion of Specialized Treatment Centers for Rare Diseases in Emerging Markets

Regulatory Support for Fast-track Approvals of Novel Therapies

4. GLOBAL MARKET PERSPECTIVE

World Alpha Mannosidosis Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030

World Recent Past, Current & Future Analysis for Alpha Mannosidosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Alpha Mannosidosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Alpha Mannosidosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Bone Marrow Transplant (BMT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Bone Marrow Transplant (BMT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Bone Marrow Transplant (BMT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Enzyme Replacement Therapy (ERT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Enzyme Replacement Therapy (ERT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Enzyme Replacement Therapy (ERT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Type I by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Type I by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Type I by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Type II by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Type II by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Type II by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Type III by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Type III by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Type III by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

UNITED STATES

Alpha Mannosidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)

USA Recent Past, Current & Future Analysis for Alpha Mannosidosis by Treatment - Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

USA Historic Review for Alpha Mannosidosis by Treatment - Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

USA 15-Year Perspective for Alpha Mannosidosis by Treatment - Percentage Breakdown of Value Sales for Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) for the Years 2015, 2025 & 2030

USA Recent Past, Current & Future Analysis for Alpha Mannosidosis by Indication - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

USA Historic Review for Alpha Mannosidosis by Indication - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

USA 15-Year Perspective for Alpha Mannosidosis by Indication - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030

CANADA

Canada Recent Past, Current & Future Analysis for Alpha Mannosidosis by Treatment - Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Canada Historic Review for Alpha Mannosidosis by Treatment - Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Canada 15-Year Perspective for Alpha Mannosidosis by Treatment - Percentage Breakdown of Value Sales for Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) for the Years 2015, 2025 & 2030

Canada Recent Past, Current & Future Analysis for Alpha Mannosidosis by Indication - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Canada Historic Review for Alpha Mannosidosis by Indication - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Canada 15-Year Perspective for Alpha Mannosidosis by Indication - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030

JAPAN

Alpha Mannosidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)

Japan Recent Past, Current & Future Analysis for Alpha Mannosidosis by Treatment - Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Japan Historic Review for Alpha Mannosidosis by Treatment - Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Japan 15-Year Perspective for Alpha Mannosidosis by Treatment - Percentage Breakdown of Value Sales for Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) for the Years 2015, 2025 & 2030

Japan Recent Past, Current & Future Analysis for Alpha Mannosidosis by Indication - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Japan Historic Review for Alpha Mannosidosis by Indication - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Japan 15-Year Perspective for Alpha Mannosidosis by Indication - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030

CHINA

Alpha Mannosidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)

China Recent Past, Current & Future Analysis for Alpha Mannosidosis by Treatment - Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

China Historic Review for Alpha Mannosidosis by Treatment - Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

China 15-Year Perspective for Alpha Mannosidosis by Treatment - Percentage Breakdown of Value Sales for Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) for the Years 2015, 2025 & 2030

China Recent Past, Current & Future Analysis for Alpha Mannosidosis by Indication - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

China Historic Review for Alpha Mannosidosis by Indication - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

China 15-Year Perspective for Alpha Mannosidosis by Indication - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030

EUROPE

Alpha Mannosidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)

Europe Recent Past, Current & Future Analysis for Alpha Mannosidosis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

Europe Historic Review for Alpha Mannosidosis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Alpha Mannosidosis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030

Europe Recent Past, Current & Future Analysis for Alpha Mannosidosis by Treatment - Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Europe Historic Review for Alpha Mannosidosis by Treatment - Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Alpha Mannosidosis by Treatment - Percentage Breakdown of Value Sales for Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) for the Years 2015, 2025 & 2030

Europe Recent Past, Current & Future Analysis for Alpha Mannosidosis by Indication - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Europe Historic Review for Alpha Mannosidosis by Indication - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Alpha Mannosidosis by Indication - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030

FRANCE

Alpha Mannosidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)

France Recent Past, Current & Future Analysis for Alpha Mannosidosis by Treatment - Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

France Historic Review for Alpha Mannosidosis by Treatment - Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

France 15-Year Perspective for Alpha Mannosidosis by Treatment - Percentage Breakdown of Value Sales for Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) for the Years 2015, 2025 & 2030

France Recent Past, Current & Future Analysis for Alpha Mannosidosis by Indication - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

France Historic Review for Alpha Mannosidosis by Indication - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

France 15-Year Perspective for Alpha Mannosidosis by Indication - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030

GERMANY

Alpha Mannosidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)

Germany Recent Past, Current & Future Analysis for Alpha Mannosidosis by Treatment - Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Germany Historic Review for Alpha Mannosidosis by Treatment - Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Germany 15-Year Perspective for Alpha Mannosidosis by Treatment - Percentage Breakdown of Value Sales for Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) for the Years 2015, 2025 & 2030

Germany Recent Past, Current & Future Analysis for Alpha Mannosidosis by Indication - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Germany Historic Review for Alpha Mannosidosis by Indication - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Germany 15-Year Perspective for Alpha Mannosidosis by Indication - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030

ITALY

Italy Recent Past, Current & Future Analysis for Alpha Mannosidosis by Treatment - Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Italy Historic Review for Alpha Mannosidosis by Treatment - Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Italy 15-Year Perspective for Alpha Mannosidosis by Treatment - Percentage Breakdown of Value Sales for Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) for the Years 2015, 2025 & 2030

Italy Recent Past, Current & Future Analysis for Alpha Mannosidosis by Indication - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Italy Historic Review for Alpha Mannosidosis by Indication - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Italy 15-Year Perspective for Alpha Mannosidosis by Indication - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030

UNITED KINGDOM

Alpha Mannosidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)

UK Recent Past, Current & Future Analysis for Alpha Mannosidosis by Treatment - Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UK Historic Review for Alpha Mannosidosis by Treatment - Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UK 15-Year Perspective for Alpha Mannosidosis by Treatment - Percentage Breakdown of Value Sales for Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) for the Years 2015, 2025 & 2030

UK Recent Past, Current & Future Analysis for Alpha Mannosidosis by Indication - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UK Historic Review for Alpha Mannosidosis by Indication - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UK 15-Year Perspective for Alpha Mannosidosis by Indication - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030

REST OF EUROPE

Rest of Europe Recent Past, Current & Future Analysis for Alpha Mannosidosis by Treatment - Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for Alpha Mannosidosis by Treatment - Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Europe 15-Year Perspective for Alpha Mannosidosis by Treatment - Percentage Breakdown of Value Sales for Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) for the Years 2015, 2025 & 2030

Rest of Europe Recent Past, Current & Future Analysis for Alpha Mannosidosis by Indication - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for Alpha Mannosidosis by Indication - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Europe 15-Year Perspective for Alpha Mannosidosis by Indication - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030

ASIA-PACIFIC

Alpha Mannosidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)

Asia-Pacific Recent Past, Current & Future Analysis for Alpha Mannosidosis by Treatment - Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Alpha Mannosidosis by Treatment - Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Asia-Pacific 15-Year Perspective for Alpha Mannosidosis by Treatment - Percentage Breakdown of Value Sales for Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) for the Years 2015, 2025 & 2030

Asia-Pacific Recent Past, Current & Future Analysis for Alpha Mannosidosis by Indication - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Alpha Mannosidosis by Indication - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Asia-Pacific 15-Year Perspective for Alpha Mannosidosis by Indication - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030

REST OF WORLD

Rest of World Recent Past, Current & Future Analysis for Alpha Mannosidosis by Treatment - Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of World Historic Review for Alpha Mannosidosis by Treatment - Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of World 15-Year Perspective for Alpha Mannosidosis by Treatment - Percentage Breakdown of Value Sales for Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT) for the Years 2015, 2025 & 2030

Rest of World Recent Past, Current & Future Analysis for Alpha Mannosidosis by Indication - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of World Historic Review for Alpha Mannosidosis by Indication - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of World 15-Year Perspective for Alpha Mannosidosis by Indication - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030

COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)	% VALIDATED RESEARCH *
AllStripes	%
Chiesi Farmaceutici SpA	%
Chiesi Global Rare Disease	%
Chiesi Limited	%
Chiesi Pharma AB	%
Chiesi USA, Inc.	%
Creative BioMart	%
SmartPharm Therapeutics	%

* Login to Participate & View Data Stacks

* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlass^TM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.

View All Companies...

PARTICIPATE NOW!

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: [email protected]

DIFFERENTIATORS

Integrity Trust Transparency

Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .

What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).

WHAT SETS US APART

FULL STACK DATA ACCESS

Primary Research Cluster Data
Influencer Engagement Stats
Evidence of Primary Research
List of Companies Engaged
Hundreds of Pages of Research
Peer Collaborative Interactions
Enterprise Data Exchanges
MarketGlassTM Platform Insider
Geographic Pricing Dynamics
Competitive Shares by Country
Brand Curation & Insights
Domain Expert Pool

Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.

Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.

Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.

Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.

Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.

Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.

Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.

Scroll